Survey findings show that although physicians view continuous glucose monitoring (CGM) as transformative, systemic barriers persist, leading to variable adoption across clinical practices.
Publication|Articles|November 4, 2024
Supplements and Featured Publications
- Achieving Excellence in Peripheral Artery Disease and Chronic Limb-Threatening Ischemia Care
Achieving Excellence in Peripheral Artery Disease and Chronic Limb-Threatening Ischemia Care
Listen
0:00 / 0:00
Advertisement
This resource was sponsored by Johnson & Johnson.
This actionable resource presents best practices on developing a standardized care program that includes workflow integration, provider engagement, and program assessment tools for managing peripheral artery disease and chronic limb-threatening ischemia.
Advertisement
Related to this article
Physicians to Discuss 2026 Oncology Care Index at Patient-Centered Oncology Care®, Premier Annual AJMC® Event Starting Today in Nashville |
60% of Community Physicians Say Clinical Trial Options Are Limited; 93% Say Pragmatic Designs Would Help
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.
Advertisement
Advertisement